trending Market Intelligence /marketintelligence/en/news-insights/trending/u8Jla3axVYWF0BBshVN4gQ2 content esgSubNav
In This List

Clinuvel's rare disorder therapy faces reimbursement challenge in UK

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Clinuvel's rare disorder therapy faces reimbursement challenge in UK

The U.K.'s National Institute for Health and Care Excellence, or NICE, recommended against granting reimbursement for Scenesse to treat erythropoietic protoporphyria, in draft guidelines.

Scenesse, or afamelanotide, which is marketed by Australian firm Clinuvel Pharmaceuticals Ltd, was approved by the European Medicines Agency in 2014. However, the therapy is not reimbursed by the English National Health Service.

A final recommendation is expected to be made by the Highly Specialised Technologies Evaluation Committee in May 2018.

The company said it has maintained a transparent uniform price for the treatment applicable to all European countries, including Switzerland, the implementation of which would not exceed the National Health Service budget threshold for new technologies.